

Resource Summary Report

Generated by [ASWG](#) on Aug 2, 2026

Asterand

RRID:SCR_010703

Type: Tool

Proper Citation

Asterand (RRID:SCR_010703)

Resource Information

URL: <http://www.asterand.com/>

Proper Citation: Asterand (RRID:SCR_010703)

Description: Provides human tissue for drug discovery scientists. * Human Biospecimens: Frozen & Fixed Human Tissues; Human RNA/DNA; Human Primary Cells / Cell lines; Custom Procurement; Oncology tissue, biofluid and RNA sets at special prices * Human Tissue-Based Services: Gene Expression, Molecular Pathology, Biochemical Pharmacology, Metabolism and Toxicity * Predictive Human Disease Models

Abbreviations: Asterand

Synonyms: Asterand: Partners in Human Tissue Research, Asterand plc

Resource Type: biomaterial supply resource, tissue bank, material resource

Resource Name: Asterand

Resource ID: SCR_010703

Alternate IDs: nlx_88875

Record Creation Time: 20220129T080300+0000

Record Last Update: 20260801T191021+0000

Ratings and Alerts

No rating or validation information has been found for Asterand.

No alerts have been found for Asterand.

Data and Source Information

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Badoer C, et al. (2016) Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples. Oncotarget, 7(49), 81357.

Park BJ, et al. (2014) Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses. BMC research notes, 7, 7.

Mesri M, et al. (2013) Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues. PloS one, 8(11), e78885.

Liu S, et al. (2012) MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS genetics, 8(6), e1002751.

Huo Q, et al. (2012) Developing a nanoparticle test for prostate cancer scoring. Journal of translational medicine, 10, 44.

, et al. (2005) Corporate Activity - Mergers and Acquisition. Pharmaceutical & diagnostic innovation, 3(10), 18.